Hard to say what the bottom is. Looking for an entry point myself for further diversification in the CNS space. All the noise doesn't bother me. The drug works or it doesn't and so far we've seen a positive trend. All that said, its a very negative sentiment in the bio world right now and its going to be a long haul before results come out. Positive is the company is sitting on 200 million in cash so an equity raise is likely out of the picture. There may be some risk with the DOJ situation. Just hard to say. Only speculative money here for me.
News 
Market Data 
Discover 
